“C. elegans is a really powerful model for ageing research and with Magnitude Biosciences, we want to bring that power to a wider group of people”
David has 20 years experience with C. elegans, learning as a postdoc with David Gems, Ronald Plasterk and Erik Jorgensen. He discovered a mutation in the E. coli bacteria that increases C. elegans lifespan (Virk et al 2012) and has characterised a number of compounds that slow ageing (Bass et al 2007, Virk et al 2012, Cabreiro et al 2013). He led a manual screen of 1000 E. coli mutants to find those that increase lifespan (Virk et al 2016) and development of a defined nutrient media to increase reproducibility (Maynard et al 2018).
However, to improve throughput and data quality, David has turned to automation. He brought together the Magnitude Biosciences team as the right people to design, implement and deliver a reliable automated service that can bring increases in productivity to the whole field.
With a deep mathematical understanding, Chris is the genius behind the software at the heart of the Healthspan Machine. He has over 15 years experience adapting imaging technology to answer questions in biology and is an Associate Professor at Durham University Physics Department
Fred has a PhD in Cell Biology and many years experience working in the life sciences CRO environment. She brings substantial Business Developments skills to Magnitude Biosciences.
With decades of experience helping small tech companies fulﬁl their potential, John brings commercial expertise and first-hand knowledge of the investment community. John has worked around the world and is building Magnitude’s global business.
Adelaide has over a decade of experience of working with the nematode C. elegans. She has previously organised a manual lifespan screen of a 1000 E. coli strains, using 100 worms on each strain (Virk et al 2016). Her attention to detail and worm picking skills are of the highest level, meaning that your worm strains and experiments are in good hands!
Funded by the ERDF Intensive Industrial Innovative Programme and a graduate of Durham University (BSc) and Bath University (MSc), Giulia brings a wide range of interests to Magnitude Bioscience, including neurodegenerative disease and the role of the microbiome in health and disease.
Contact us to discuss your role in our company
A native of Scotland, Gordon gained his PhD at Glasgow with further training at Ciba Geigy AG, Switzerland and the University of Colorado. He won the Glenn Award for Research in Biological Mechanisms of Aging, a senior scholarship from the Ellison Medical Foundation and the Tenovus Award for Biomedical Research. Gordon serves on many national advisory panels in the UK and USA including the National Institute on Aging’s Board of Scientific Councillors and the Chair of Biological Sciences at the Gerontology Society of America.
Gordon’s lab is focused on understanding the role of aging in the origins of age-related chronic disease. He led the identification of pharmacological interventions in aging by publishing the first pharmacological lifespan extension in an animal in a high-profile journal, prompting many efforts to find compounds that extend lifespan in different animal models.
His lab utilizes molecular genetics, biochemistry, proteomics and metabolomics, as well as C. elegans, which ages rapidly but exhibits many characteristics of human aging, and has identified scores of chemical compounds that suppress disease phenotypes and extend lifespan. Many of these compounds promote protein homeostasis, which usually fails during normal aging and is a factor in diseases such as Alzheimer’s and Parkinson’s.
Gordon has partnered with numerous biotechnology companies in sponsored research agreements and has strong collaborations in pre-clinical aging research on diseases such as osteoporosis and Parkinson’s disease.
Eveleigh-Fenton Chair of Applied Microbiology at Rutgers University and Distinguished Professor of Microbiology at Shanghai Jiao Tong University. He is a senior editor of the ISME Journal and associate editor of the journal Microbiome, a fellow of American Academy of Microbiology and a senior fellow of Canadian Institute for Advanced Research (CIFAR). He serves on Scientific Advisory Board for the Center for Microbiome Research and Education of American Gastroenterology Association (AGA).
Liping pioneered the approach of applying metagenomics-metabolomics integrated tools and dietary intervention for systems understanding and predictive manipulation of gut microbiota to improve human metabolic health. Following the logic of Koch’s postulates, he found that an endotoxin-producing opportunistic pathogen isolated from an obese human gut can induce obesity in germfree mice. His publications in Science and EBioMedicine showed that dietary modulation of gut microbiota can significantly alleviate metabolic diseases including a genetic form of obesity in children and type 2 diabetes in adults. Science magazine featured a story on how he combines traditional Chinese medicine and gut microbiota study to understand and fight obesity.
Associate Professor, Division of Geriatrics and Gerontology, Department of Medicine, UW School of Medicine and Public Health, Associate Director of Research, Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital Madison.
Rozalyn leads the Metabolism of Aging research program at the UW Madison SMPH Department of Medicine. Her research focuses on metabolic status and loss of metabolic integrity as critical factors contributing to increased disease vulnerability as a function of age. One of her major goals is to identify mechanisms of delayed aging by caloric restriction using mouse and monkey models. She is a Fellow of the Gerontological Society of America and a Fellow of the American Aging Association. Her research is supported by National Institutes of Health/National Institute on Aging, the American Federation for Aging Research, the Glenn Foundation for Medical Research, and the US Department for Veterans Affairs.